Summary: ArteFill, the successor product to Artecoll, is an injectable wrinkle filler composed of polymethylmethacrylate microspheres and bovine collagen, which offers long-lasting and probably permanent augmentation of wrinkles and skin contour deformities. The pivotal U.S. Food and Drug Administration study consisted of 251 subjects at eight centers in the United States who received injections of ArteFill or bovine collagen dermal filler (control) in 1334 wrinkles of the glabella, nasolabial folds, radial upper lip lines, and corners of the mouth. The efficacy data generated by masked observers using a photographic Facial Fold Assessment Scale demonstrated a significant improvement with ArteFill compared with collagen at 6 months (p Ͻ 0.001) in the nasolabial folds. In the ArteFill group, 12-month follow-up was obtained for 111 subjects (86.7 percent) and showed persistence of significant wrinkle correction. A subgroup of 69 patients who received ArteFill were recalled 4 to 5 years later. Five patients reported six late adverse events that occurred from 2 to 5 years after the initial injection; four of the adverse events were mild cases of lumpiness and two were severe. The total number of late adverse events was six of 272 (2.2 percent) wrinkles injected. Among the 272 wrinkles evaluated at 5 years, two events (0.7 percent) in one patient were rated as severe (a nodular, minimally inflammatory to noninflammatory reaction in both nasolabial folds). Investigator Facial Fold Assessment ratings at 4 to 5 years were improved from baseline by 1.67 points (p Ͻ 0.001). (Plast. Reconstr. Surg. 118 (Suppl.): 64S, 2006.) 
O
ver the past several decades, numerous attempts have been made to develop safe biological or synthetic materials to permanently fill wrinkles and scars. 1, 2 Virtually all biological materials, however, are ultimately resorbed, and previously used synthetic materials have been associated with side effects, such as migration, granuloma formation, and late allergic reactions. 3, 4 To overcome some of the problems associated with artificial skin fillers, Artecoll was developed in Germany in 1994 to be a permanent, injectable implant. As of this article's acceptance for publication in Plastic and Reconstructive Surgery, ArteFill, a product of Artes Medical, had not yet been approved by the U.S. Food and Drug Administration. ArteFill has the same composition as Artecoll, but nanoparticles have been further reduced and the sphere size is more uniform. 5 To avoid confusion in the present article, Artecoll is referred to as ArteFill. 6 Once approved by the U.S. Food and Drug Administration, Artecoll will be marketed as ArteFill in the United States and internationally.
ArteFill consists of homogenous polymethylmethacrylate microspheres evenly suspended in a solution of partly denatured 3.5% collagen, which serves as a vehicle for deep-dermal implantation. 7 All microspheres have a defined size of 30 to 42 m in diameter; are completely polymerized; and have a smooth, round surface. Because of the smooth surface of the polymethylmethacrylate microspheres, each microsphere becomes encapsulated by the patient's own collagen fibers, thereby preventing dislocation.
ArteFill consists of 20 volume percent polymethylmethacrylate microspheres evenly suspended in 80 volume percent U.S. bovine collagen solution per syringe. After deep dermal injection of ArteFill, the collagen carrier is degraded by the body within 1 to 3 months and completely replaced by the body's own collagen at a similar rate, ensuring a steady augmentation result. Because the polymethylmethacrylate microspheres are nonbiodegradable and too large to migrate or to be phagocytosed by macrophages, the tissue augmentation is expected to be permanent, consisting of 80 volume percent autologous connective tissue.
Artecoll, ArteFill's predecessor, has been approved and available in over 50 countries in the world since 1994. Since its introduction in 1994, an estimated 400,000 patients have been treated, with a reported complication rate of 0.01 percent. 6, 8 On February 28, 2003, the U.S. Food and Drug Administration General and Plastic Surgery Devices Advisory Panel recommended that ArteFill be approved, with conditions, for marketing in the U.S. ArteFill is expected to become the first permanent injectable wrinkle filler to gain U.S. Food and Drug Administration approval.
The need to closely monitor and report any long-term benefits and late adverse events when discussing a permanent filler material is critical to the successful application of a product such as ArteFill. The purpose of the present report is to summarize the U.S. Food and Drug Administration United States Clinical Trial and to update the readership on the 4-to 5-year outcomes following injection of ArteFill.
MATERIALS AND METHODS
The purpose of the U.S. Food and Drug Administration study was to compare the safety and efficacy of ArteFill injections with those of collagen (Zyderm II or Zyplast) in the glabellar frown lines, nasolabial folds, radial upper lip lines, and corners of the mouth (marionette). The primary objectives of the study were to compare the cosmetic correction provided by ArteFill at the end of 6 months to that of Zyderm/Zyplast over the same time period and to explore the safety of ArteFill at 6 and 12 months as an injectable implant for correction of contour deformities of the dermis of the face. The secondary objectives of the study were to characterize the physician's assessment of success with respect to how closely the treatment met the physician's expectations for correction and to characterize the subject's assessment of satisfaction with respect to the subject's personal expectations. Although physicians were not masked as to the identity of the treatment, subjects were not told which treatment they received until after they had completed the 6-month evaluation.
The study was performed at eight centers (four plastic surgery centers and four dermatology centers), with institutional review board approval and informed consent from all subjects. The study was controlled and randomized, with potential subjects agreeing to be assigned to either the ArteFill or control group. The subjects and evaluators were masked and unaware of which injection material they received (double-blinded). Inclusion and exclusion criteria were strict and have previously been published. Efficacy was measured by three masked observers using the Facial Fold Assessment Scale to rate wrinkles on the subject's photographs. 10 Investigator assessment of success was recorded at 1, 3, and 6 months using the following scale: 1 ϭ completely successful, 2 ϭ very successful, 3 ϭ moderately successful, 4 ϭ somewhat successful, and 5 ϭ not at all successful. Subject assessment of satisfaction was recorded at 1-, 3-, and 6-month intervals using the following scale: 1 ϭ very satisfied, 2 ϭ satisfied, 3 ϭ somewhat satisfied, 4 ϭ dissatisfied, and 5 ϭ very dissatisfied.
4-to 5-Year Follow-Up Data
All study participants were invited to return for 4-to 5-year follow-up. As an inducement, a small financial payment ($100) was offered. A subgroup of 69 patients who received ArteFill returned 4 to 5 years after their initial treatment. These 69 patients underwent clinical and photographic evaluation and were again rated for efficacy using the Facial Fold Assessment Scale. Safety information and adverse events were also recorded at 4-to 5-year follow-up. The data in the present report were tabulated as of September 9, 2005 , the cutoff date for this portion of the study. A vigorous effort is still underway to follow up as many of the original study patients as possible; thus, ultimately, a final report will be submitted on a larger number of patients.
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Injection Technique
Before injection, topical anesthetic cream/ ointment and, for the upper lip, local anesthesia was used when indicated by the investigator. The dermal layer used for ArteFill implantation is shown in Figure 1 . The method of implanting ArteFill is more technique sensitive than that for injecting collagen. The "tunneling technique," moving the needle in a linear fashion back and forth just beneath the wrinkle, was used. Because the viscosity of ArteFill is three times higher than that of Zyplast, a higher constant pressure was applied throughout the injection procedure. A 26-gauge, half-inch-long needle was used. The thickness of the needle and skin were used to help determine depth of injection. The thickness of facial skin varies between 0.2 mm (eyelids), 0.4 mm (nasolabial folds), and 0.8 mm (glabellar frown lines). 11 The thickness of the skin in a deep crease is diminished to approximately one-fourth of its normal thickness. At the start of the procedure, the needle was tested by squeezing a small quantity of ArteFill out of the tip. ArteFill was then implanted deeply intradermally (e.g., into the reticular dermis just above the junction between dermis and subcutaneous fat). If ArteFill was injected into the papillary dermis, causing a blanching effect, the injection was stopped and the needle was placed at a deeper level. At the end of implantation, the implant was evenly massaged with the fingertip, and slight pressure was applied to any detected lump. Subjects were advised that there would be some swelling for the first 12 to 24 hours and that areas of light pink coloration along the injection sites might be present for 2 to 5 days. They were also advised to minimize mimetic activity for 1 to 2 days.
Statistical Analysis
Adverse events were described by counts of events and counts of subjects experiencing adverse events. Counts of elevated immunoglobulin G levels were also provided. Tests for treatment group differences in number of treatments and quantity of product were made using independent t tests. Nonparametric tests were used for ratings variables. Groups were compared with MannWhitney U tests for improvements in observerrated and investigator-rated Facial Fold Assessment Scale scores and for investigator success ratings and subject satisfaction ratings. Withingroup tests for improvements in the ArteFill treatment group were made using Wilcoxon matchedpairs signed ranks data to accommodate the 12-month observations. Rater reliability for observer Facial Fold Assessment Scale ratings was evaluated using intraclass correlation.
RESULTS
There were 251 subjects entered into the study. One hundred twenty-eight subjects received ArteFill (11 men and 117 women), and 123 subjects (11 men and 112 women) received the collagen control. The mean age of the ArteFill subjects was 53.2 years (range, 28 to 82 years) and the mean age of the controls was 51.2 years (range, 29 to 78 years). Of these 251 subjects, 247 had at least one follow-up visit (98.4 percent) and 233 (92.8 percent) had 6-month follow-up visits. In the Ar- teFill group, 12-month follow-up was obtained for 111 subjects (86.7 percent). Because ArteFill treatment was offered to all subjects in the collagen group at 6-month follow-up, no 12-month follow-up could be obtained for the collagen group. Of the 116 collagen subjects who completed the 6-month follow-up evaluation, 106 (91 percent) were treated with ArteFill.
ArteFill was injected into the glabellar frowns of 81 subjects, nasolabial folds of 108 subjects, upper lip lines of 69 subjects, and mouth corners of 86 subjects; whereas collagen was injected into the glabellar frowns of 86 subjects, nasolabial folds of 104 subjects, upper lip lines of 59 subjects, and mouth corners of 87 subjects. In total, 1334 wrinkles were injected: 320 glabellar frowns, 420 nasolabial folds, 253 lip lines, and 341 mouth corners were treated in the 251 subjects.
The number of treatments to each of the facial areas (i.e., glabellar frowns, nasolabial folds, radial upper lip lines, and corner of mouth lines) were not significantly different (p ϭ 0.316 to p ϭ 0.974) between ArteFill and the controls (Fig. 2) . Almost twice as much collagen as ArteFill was used at each of the four injection sites (Fig. 3) , a statistically significant difference (p Ͻ 0.001 in each case).
Results of Primary Objectives
Although adverse reactions were uncommon in either group, more redness and swelling and more lumpiness at the injection site was noted in the collagen group. There were a total of 27 adverse events in the ArteFill group compared with 38 in the collagen controls. These numbers were not statistically significant. One subject underwent "incidental" removal and/or drainage in the ArteFill group related to excision of an actinic keratosis in the vicinity of the previous ArteFill injection, and two subjects in the collagen group required removal and/or drainage for abscesses (Table 1) .
Serum immunoglobulin G levels were elevated in one subject undergoing ArteFill implantation after 1 month. Levels were elevated in one subject at 1, 3, and 6 months after collagen injection. There was no clinically significant findings in these patients. Table 2 summarizes improvement over time in the masked observers' Facial Fold Assessment Scale ratings. Observations 1 month after injection showed no statistically significant difference between the two groups for nasolabial folds, upper lip lines, or mouth corners, whereas the control treatment was more effective (p ϭ 0.004) than ArteFill for glabellar folds. By 3 months, the masked observers' ratings showed a statistically significantly greater improvement in the nasolabial folds (p Ͻ 0.001) and the corner of the mouth wrinkles (p ϭ 0.001) in the ArteFill group when compared with collagen. Averaged across facial areas, the overall result was also significant (p Ͻ 0.001). At 6 months after injection, the ArteFill group was statistically better (p Ͻ 0.001) than the Volume 118, Number 3S • Progress Report on ArteFill
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collagen injection in the nasolabial fold and overall (p Ͻ 0.001). Facial Fold Assessment Scale reliability among the three masked raters ranged from 0.835 for the glabellar frowns to 0.900 for the corner of the mouth lines. Table 3 summarizes improvement in investigators' Facial Fold Assessment Scale ratings over time. Unlike masked observers, who rated from photographs, investigators were not masked and rated their live expe- rience with subjects against the reference photographs of the Facial Fold Assessment Scale. At 1 month, significantly greater improvement in glabellar folds was seen with control than with ArteFill (p ϭ 0.034), whereas significantly greater improvement in mouth corners was seen with ArteFill than with control (p ϭ 0.041). By 3 months, all facial areas except for glabellar folds (p ϭ 0.317) showed significantly greater improvement with ArteFill than with control (p Ͻ 0.001 in each case). The overall average was also significantly greater for ArteFill (p Ͻ 0.001). By 6 months, all four facial areas and the overall average showed significantly greater improvement with ArteFill than with control (p Ͻ 0.001).
Results of Secondary Objectives
Investigator success ratings over time are summarized in Figure 4 . As shown in the figure, the ratings for the two groups were similar at 1 month. However, by 3 months and 6 months, significantly more success was noted in the ArteFill group than in the control group (p ϭ 0.007 to p Ͻ 0.001). By 6 months, ArteFill ratings Volume 118, Number 3S • Progress Report on ArteFill were generally in the very successful range, whereas collagen ratings were generally in the somewhat successful range. A similar presentation for subject ratings of satisfaction is shown in Figure 5 . No significant differences between treatment groups was noted at 1 month. By 3 months, the subjects in the ArteFill group reported significantly greater satisfaction than those in the control group (p ϭ 0.038 to p Ͻ 0.001). At 6 months, the subjects in the ArteFill group continued to report significantly greater satisfaction than the control group subjects (p Ͻ 0.001 in each case). By 6 months, the means for the ArteFill group were generally in the Satisfied range while the means for the control group were generally in the Dissatisfied range.
12-Month ArteFill Efficacy Analysis
Data on improvement at 12-months in Facial Fold Assessment Scale ratings was available for the 
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ArteFill group only, per protocol, because of crossover of collagen subjects to the ArteFill treatment at 6 months. Ratings from masked observers and from investigators were included.
Single group tests were computed for masked observer ratings to determine whether efficacy could be detected 12 months after treatment. The results showed significant improvement in Facial Fold Assessment Scale ratings for the each of the four facial areas and the overall average (p ϭ 0.047 to p Ͻ 0.001).
Similar tests were computed for investigator Facial Fold Assessment Scale ratings. These showed significant results in all four of the treatment areas and overall (p Ͻ 0.001 in each case). These ratings for masked observer and investigator demonstrated effectiveness 12 months after ArteFill treatment.
Investigator ratings of success and subject ratings of satisfaction in the ArteFill group at 12 months are presented in Figures 4 and 5 , respectively. The success and satisfaction ratings remained high for the ArteFill group at 12 months.
5-Year Results and Statistical Analysis
A subgroup of 69 patients who received ArteFill were recalled 4 to 5 years later. These 69 patients underwent clinical and photographic evaluation and were again rated for efficacy using the Facial Fold Assessment Scale. Safety information and adverse events were also recorded at 4-to 5-year follow-up. Five patients reported six late adverse events: four of the adverse events were mild and two were severe. Among the 272 wrinkles evaluated at 5 years, two events (0.7 percent) in one patient were rated as severe (a nodular minimally to noninflammatory reaction in both nasolabial folds). The patient was treated with steroid injections, and the event is in the process of resolving, having been rated recently as mild. The patient is happy with the result and may or may not return for further treatment of the event. The other four patients had mild events reported as lumpiness in the left glabellar fold in one, the left radial wrinkle line in one, the left marionette line in one, and the left nasolabial fold in one. In one patient with mild lumpiness in the left marionette line, the lump was simply excised by a small intraoral incision. These six late adverse events were reported to the investigators from 2 to 5 years after the initial injection.
Investigator Facial Fold Assessment Scale ratings at 4 or 5 years were improved from baseline by 1.67 points (p Ͻ 0.001); 81.8 percent of subjects reported that they were either satisfied or very satisfied; 95.5 percent reported that they were at least somewhat satisfied; 88.6 percent were rated as very successful or completely successful by investigators; and 97.7 percent were rated as at least moderately successful. Forty-three of the 69 patients had no other surgical procedures (i.e., midface lift) following ArteFill injection 4 to 5 years earlier. Facial Fold Assessment Scale ratings in these patients were conducted by three blinded observers (Fig. 6) . Masked observer Facial Fold Assessment Scale ratings at 5 years were improved from baseline by 1.22 points (p Ͻ 0.001).
DISCUSSION
The results of this study show ArteFill to be a safe and effective soft-tissue filler. Although ArteFill had fewer adverse events reported throughout the 12-month safety study period compared with collagen (Zyderm/Zyplast) in a 6-month study period, these results were not statistically significant. ArteFill was more effective than collagen for correction of nasolabial folds in masked observer ratings at the 6-month effectiveness study period. No statistically significant difference was noted between masked observer ratings for ArteFill and collagen in the other injection sites; however, the quantity of ArteFill used was nearly half that of collagen. Investigators' success ratings for ArteFill were superior to those for collagen at 6 months for each of the four injection sites. Subjects' satisfaction ratings for the ArteFill group were also higher Volume 118, Number 3S • Progress Report on ArteFill
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than for collagen in each of the injection sites at 6 months after implantation.
A preliminary product used in humans by the same inventor, before Artecoll, was called Arteplast. 12 The original suspension consisted of 30-to 42-m-diameter polymethylmethacrylate microspheres in gelatin. The first clinical trials were conducted under the supervision of the Ethical Commission of Frankfurt University in 1989. One hundred eighty-seven volunteers received Arteplast subdermally. In this group, plus the 400 subjects who received Arteplast up until its replacement by Artecoll in 1994, a total of 15 (2.5 percent) developed foreign body granulomas from 6 to 18 months after injection. 6 The majority of these were treated with intralesional steroid injection and rarely with surgical excision. In 1994, a new purification and washing technique was introduced. 6 The sieving process was changed from a nylon fabric mesh to a metal mesh, and a complex washing and ultrasound procedure was devised that removed virtually all nanoparticles and electrical surface charges, which were thought to be the cause of foreign body reactions and granuloma formation. Another change made at the same time was the use of collagen as a carrier to replace the gelatin carrier, which is resorbed too quickly and thereby permits clumping of the particles. The improved product, named Artecoll, was brought onto the market by Rofil Medical International, Breda, Holland, in 1994 and has since been used in an estimated 400,000 patients, with a reported granulomatous reaction rate of less than 0.01 percent. 6, 8 In evaluating the literature on safety of permanent injectable fillers, it is critical for the clinician to differentiate between Arteplast, Artecoll, and ArteFill. Arteplast, Artecoll, and ArteFill have been confused with each other in the past, making accurate communication about the safety and efficacy of ArteFill difficult. 13 Electron microscopic views of polymethylmethacrylate microspheres contained in Artecoll demonstrate significant reduction of polymethylmethacrylate microparticles smaller than 30 m, compared with Arteplast (Fig. 7) . ArteFill has been further refined to meet stringent U.S. Food and Drug Administration quality requirements by removing microparticles smaller than 20 m, which now account for less than 1 percent by number. In another words, among 100 microspheres, there is less than one phagocytosable (Ͻ20 m) particle on average. The partially denatured collagen is produced from bovine hides from a closed herd located in the United States. The collagen is the same as in Artecoll, 80 percent denatured and only 20 percent native, which makes the collagen less allergenic and reduces the positive skin test to approximately 0.1 percent.
5

Biocompatibility
The chemical inertness and biocompatibility of polymethylmethacrylate has been well accepted 15, 16 In comparison, other synthetic fillers such as Teflon or silicone particles have irregular surfaces that are more prone to cause chronic granulomatous reactions. 17 Microscopically, the predominant cells seen in the reaction to Teflon or silicone particles are foreign body giant cells. In contrast, in the rare case of foreign body reaction to ArteFill, histologically, the true granulomas show broad bands of collagen fibers between microspheres, which are pushed apart, with rare lymphocytes, macrophages, and giant cells. 18 These granulomas almost always respond to intralesional injection with corticosteroids. 6, 19 In those cases that do not respond to steroids, surgical excision may be required.
Most materials that are used as biological fillers to increase the thickness of the dermis in a wrinkle line are phagocytosed within a few months. Therefore, a lasting effect can be achieved only by using either an autogenous material that becomes vascularized and survives as a graft or with nonresorbable synthetic substances. There are approximately 6 million polymethylmethacrylate microspheres in each 1 cc of ArteFill. Beneath the wrinkle crease, the microspheres act as a matrix and stimulate fibroblasts to encapsulate each individual microsphere. Collagen is used as a carrier substance that prevents clumping during injection and stimulates tissue ingrowth. The 20 volume percent polymethylmethacrylate microspheres provide the scaffold for the 80 volume percent autologous connective tissue deposition. The ArteFill serves as a filler that seems to provide structural support to the wrinkle crease, preventing further folding and allowing the dermis to regenerate in the wrinkle fold.
Treatment Areas
The glabellar lines posed little problem with injection because the dermis is thick and the underlying connective tissue provides good support of the implant (Fig. 8) . Slight overcorrection may be necessary and deeper lines may require repeat injections. It is difficult to explain the lack of statistical difference found between collagen and ArteFill in the glabellar frown region using masked observer ratings. Initial overcorrection was common for collagen treatment. However, there was a general reluctance among U.S. clinical trial investigators to inject as much ArteFill as collagen in each of the four study areas because of its permanent effect, which may account for the absence of clear-cut statistical significance, with the exception of nasolabial folds. Nevertheless, subject satisfaction ratings and investigator success ratings were higher for ArteFill at the 6-month point in each of the four study areas.
The results of nasolabial fold augmentation with ArteFill were excellent (Figs. 9) . Nasolabial creases are best supported by two to three strands of ArteFill implanted parallel and medial to the fold. During the first several days after implantation, ArteFill can be moved laterally by facial muscle movement. Care must be taken not to place the ArteFill too superficially. Otherwise, in patients with thin skin, the implant may appear erythematous for several weeks and the implant may be visualized as small white granules. A second session is often necessary for not only the nasolabial folds but other treatment areas as well. Volume 118, Number 3S • Progress Report on ArteFill Radial lip lines extend upward or downward from tiny notches in the vermilion-cutaneous border. Care must be taken in injecting the vertical wrinkles of the lip to avoid lumps. In younger patients with nice projection of the white roll, each wrinkle can be treated individually. In patients with four or more vertical lines and in whom the projection of the white roll is diminished, ArteFill can be injected transversely along the entire white roll and beneath the individual vertical lines (Fig. 10 ). There is a natural pocket between the white roll and the orbicularis oris muscle, which is easily filled centripetally from the corners of the mouth. Injection into the upper and lower lips may be painful, and field or nerve blocks with local anesthesia are recommended. ArteFill is presently not intended for injection into the vermilion of the lip.
Wrinkles at the corners of the mouth and marionette lines may be difficult to treat but often yield excellent results. First, the lower white roll itself is treated horizontally approximately 1 cm in length from the corner. Next, five to 10 vertical and horizontal threads of ArteFill should be implanted using a criss-crossing technique. This supports the region and slightly lifts the corners of the mouth. The skin is thin in this area, and superficial injection may lead to telangiectasias. Preferably, ArteFill should be implanted in many different tunnels in two or more sessions. Injection of ArteFill into the orbicularis oris muscle is to be avoided, as it may result in the formation of nodules that can be palpated in the wet mucosa. The marionette lines that extend vertically from the corners of the mouth down to the mandibular border can be improved by linear threading combined with deep intradermal criss-cross injection of ArteFill.
5-Year Outcomes
Clinical and photographic review of the 69 patients who returned at 4 to 5 years for follow-up Plastic and Reconstructive Surgery • September 1 Supplement, 2006 substantiated our earlier impressions of the duration of ArteFill. At 5 years, the results actually looked better then they did during the period from 3 months to 1 year after injection (Figs. 9  through 12 ). It is difficult to know the exact mechanism, but because ArteFill may be considered a partially living implant, there seems to be a gradual increase in the amount of collagen deposition around the microspheres. From a safety point of view, it is critical to continue rigorous follow-up of these patients or any patient receiving a potentially permanent injection. As of September 9, 2005 , when this phase of the study was statistically analyzed, five patients reported six late adverse events: four of the adverse events were mild and two were severe. Among the 272 wrinkles evaluated at 5 years, two events (0.7 percent) in one patient were rated as severe (a nodular minimally inflammatory to noninflammatory reaction in both nasolabial folds). The patient was treated with steroid injections, and the event is in the process of resolving, having been rated recently as mild. The patient is happy with the result and may or may not return for further treatment of the event. In conclusion, it appears that late adverse events were rare with the use of ArteFill and can be successfully treated with corticoid injections. The other four patients had mild events reported as lumpiness in the left glabellar fold in one, the left radial wrinkle line in one, the left marionette line in one, and the left nasolabial fold in one. In one patient with mild lumpiness in the left marionette line, the lump was simply excised by a small intraoral incision. These six late adverse events were reported to the investigators from 2 to 5 years after the initial injection.
CONCLUSIONS
The ability to measure the effect of cosmetic treatments, such as wrinkle fillers, has suffered Volume 118, Number 3S • Progress Report on ArteFill
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from the lack of a validated objective rating scale. The authors hope that the successful use of a photographic Facial Fold Assessment Scale for this U.S. Food and Drug Administration study will encourage development and adoption of similar scales for cosmetic treatment evaluations.
This study has demonstrated the safety of ArteFill relative to collagen control, as measured by relative rates of adverse events. It has demonstrated the effectiveness of ArteFill relative to collagen control for treatment of nasolabial folds, as measured by the objective rating scale using masked raters. The effectiveness of ArteFill was demonstrated for all areas treated, using the important outcome measures of investigator success rating and subject satisfaction.
Ratings of wrinkle depth using the Facial Fold Assessment Scale by masked observers showed improvement from baseline by 1.22 points (p Ͻ 0.001) at 5 years after injection. In conclusion, it appears that improvements from ArteFill are stable for at least 4 to 5 years, and at this point in time, the development of late adverse events appears to be relatively uncommon. 
